Preoperative Treatment of Locally Advanced Rectal Cancer

In a trial comparing preoperative chemoradiotherapy and FOLFOX in patients with rectal cancer undergoing sphincter-sparing surgery, 5-year disease-free survival was 80.8% with FOLFOX and 78.6% with chemoradiotherapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-07, Vol.389 (4), p.322-334
Hauptverfasser:	Schrag, Deborah, Shi, Qian, Weiser, Martin R., Gollub, Marc J., Saltz, Leonard B., Musher, Benjamin L., Goldberg, Joel, Al Baghdadi, Tareq, Goodman, Karyn A., McWilliams, Robert R., Farma, Jeffrey M., George, Thomas J., Kennecke, Hagen F., Shergill, Ardaman, Montemurro, Michael, Nelson, Garth D., Colgrove, Brian, Gordon, Vallerie, Venook, Alan P., O’Reilly, Eileen M., Meyerhardt, Jeffrey A., Dueck, Amylou C., Basch, Ethan, Chang, George J., Mamon, Harvey J.
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Adult Anal Canal - surgery Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cancer therapies Chemoradiotherapy Chemoradiotherapy - adverse effects Chemoradiotherapy - methods Chemotherapy Chemotherapy, Adjuvant Colorectal cancer Death Disease-Free Survival Fluorouracil - administration & dosage Fluorouracil - adverse effects Gastroenterology Gastrointestinal Tract Cancer Hematology Humans Leucovorin - administration & dosage Leucovorin - adverse effects Neoadjuvant Therapy Neoplasm Recurrence, Local - drug therapy Neoplasm Staging Oncology Organ Sparing Treatments Oxaliplatin Oxaliplatin - administration & dosage Oxaliplatin - adverse effects Pathology Patients Pelvis Preoperative Care Preoperative Period Radiation therapy Rectal Neoplasms - mortality Rectal Neoplasms - pathology Rectal Neoplasms - surgery Rectum Review boards Sphincter Statistical analysis Surgeons Surgery Survival Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a trial comparing preoperative chemoradiotherapy and FOLFOX in patients with rectal cancer undergoing sphincter-sparing surgery, 5-year disease-free survival was 80.8% with FOLFOX and 78.6% with chemoradiotherapy.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2303269